Results 41 to 50 of about 206,115 (307)

Impact of the coronavirus disease 2019 epidemic and a free influenza vaccine strategy on the willingness of residents to receive influenza vaccines in Shanghai, China

Human Vaccines & Immunotherapeutics, 2021
The influenza vaccine is not included in China’s national immunization program. Here, we assessed influenza vaccine coverage among Shanghai residents and estimated the impacts of the coronavirus disease 2019 (COVID-19) epidemic and a hypothetical free ...
Yehong Zhou, Jing Tang, Junjie Zhang, Qiangsong Wu   +3 more
doaj   +1 more source

Roadblocks to translational challenges on viral pathogenesis. [PDF]

, 2013
Distinct roadblocks prevent translating basic findings in viral pathogenesis into therapies and implementing potential solutions in the clinic. An ongoing partnership between the Volkswagen Foundation and Nature Medicine resulted in an interactive ...
Deeks, Steven, Drosten, Christian, Picker, Louis, Subbarao, Kanta, Suzich, Joann   +4 more
core   +1 more source

N-glycosylation at the receptor binding site drives differences in receptor binding specificity between influenza B virus lineages

Journal of Virology
Receptor specificity plays a critical role in influenza virus host tropism and pathogenesis. Influenza A and influenza B viruses (FLUAVs and FLUBVs, respectively) utilize N-glycans with terminal sialic acids on glycoproteins decorating the surface of ...
Caroline K. Page, M. H. M. Mubassir, Pradeep Chopra, Lindsey Claire Gay, Ginger Geiger, Sean D. Ray, Justin D. Shepard, Rose J. Miller, Daniel Perez, Justin Bahl, Gerardus Josephus Boons, Stephen Mark Tompkins   +11 more
doaj   +1 more source

A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade

Viruses, 2020
On average, there are 3–5 million severe cases of influenza virus infections globally each year. Seasonal influenza vaccines provide limited protection against divergent influenza strains.
Brigette N. Corder, Brianna L. Bullard, Gregory A. Poland, Eric A. Weaver   +3 more
doaj   +1 more source

A review of the changes to the licensing of influenza vaccines in Europe [PDF]

, 2015
In 2014, the European Committee for Medicinal Products for Human Use (CHMP) published a draft regulatory guideline for the evaluation of influenza vaccines.
Voordouw, A.C.G. (Bettie), Wijnans, E.G. (Leonoor)   +1 more
core   +2 more sources

Aged AG129 mice support the generation of highly virulent novel mouse-adapted DENV (1-4) viruses exhibiting neuropathogenesis and high lethality

Virus Research
Dengue virus infection in humans ranges from asymptomatic infection to severe infection, with ∼2.5 % overall disease fatality rate. Evidence of neurological manifestations is seen in the severe form of the disease, which might be due to the direct ...
Gazala Siddqui, Preeti Vishwakarma, Shikha Saxena, Varun Kumar, Sneh Bajpai, Amit Kumar, Satish Kumar, Ritika Khatri, Jaskaran Kaur, Sankar Bhattacharya, Shubbir Ahmed, Gulam Hussain Syed, Yashwant Kumar, Sweety Samal   +13 more
doaj   +1 more source

Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future [PDF]

, 2014
Serological techniques commonly used to quantify influenza-specific antibodies include the Haemagglutination Inhibition (HI), Single Radial Haemolysis (SRH) and Virus Neutralization (VN) assays.
Callow, Calza, Chan, Cosma, De Jong, Farrohi, Ferrara, Fox, Frank, Fulton, Gross, Halloran, Harmon, Hierholzer, Johansson, Johansson, Kendal, Kilbourne, Montomoli, Okuno, O’Neill, Powers, Probert, Rowe, Schild, Schulman, Schulman, Scott, Sylte, Van Assen, Yewdell   +30 more
core   +3 more sources

Programmable DNA‐Peptide Hybrid Nanostructures for Potent Neutralization of Multiple Influenza a Virus Subtypes

Advanced Functional Materials, EarlyView.
A multivalent antiviral platform based on honeycomb‐shaped DNA nanostructures (HC–Urumin) is developed to enhance the potency and breadth of the host defense peptide Urumin. Through spatially patterned trimeric presentation, HC–Urumin disrupts influenza A virus entry, improves cell viability, and reduces disease severity in vivo‐offering a modular and ...
Saurabh Umrao, Abhisek Dwivedy, Payton L. Haak, Dhanush Gandavadi, Laurie A. Rund, Chi Chen, Vineetha Mareddy, Lifeng Zhou, Jinwei Duan, Ying Fang, Andrew J. Steelman, Xing Wang   +11 more
wiley   +1 more source

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

Advanced Functional Materials, EarlyView.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras, Imelda Raczkiewicz, Peggy Bouquet, Jean‐Philippe Dacquin, Jeremy Dhainaut, Anne Goffard, Christophe Volkringer   +6 more
wiley   +1 more source

Development of cross-protective influenza A vaccines based on cellular responses

Frontiers in Immunology, 2015
Seasonal influenza vaccines provide protection against matching influenza A virus (IAV) strains mainly through the induction of neutralizing serum IgG antibodies. However, these antibodies fail to confer a protective effect against mismatched IAV.
Peter Christiaan Soema, Peter Christiaan Soema, Elly evan Riet, Gideon eKersten, Gideon eKersten, Jean-Pierre eAmorij   +5 more
doaj   +1 more source